Bifidobacterium infantis ATCC 15697

Bifidobacterium infantis ATCC 15697 is a gram-positive anaerobic probiotic strain naturally dominant in the gut of breastfed infants, operating primarily through competitive exclusion of pathogens and production of short-chain fatty acids and lactic acid. It colonizes the infant intestinal mucosa by metabolizing human milk oligosaccharides (HMOs) via specialized glycosidases, lowering luminal pH and suppressing pathogenic organisms like Escherichia coli and Clostridium species.

Origin & History

Bifidobacterium infantis ATCC 15697 is a specific probiotic strain isolated from the intestine of a human infant, belonging to the B. longum subspecies infantis. As a whole genome-sequenced type strain, it is cultured in laboratory media rather than extracted from plants, and classified as a live Gram-positive anaerobic bacterium naturally associated with the infant gut microbiota.

Historical & Cultural Context

No historical or traditional medicine use is documented for this specific ATCC 15697 strain, as it is a modern laboratory-isolated probiotic identified in the 20th century. While Bifidobacterium species naturally occur in human infant guts, there is no evidence of intentional traditional therapeutic application.

Health Benefits

• Enhances beneficial gut bacteria colonization - particularly effective in premature infants, with studies showing significantly higher fecal bifidobacteria levels compared to other probiotic strains (preliminary evidence from infant trials)
• Reduces harmful gut bacteria - demonstrated significant decreases in Proteobacteria and Enterobacteriaceae (0.80% vs. 2.83% in rat studies)
• Lowers endotoxin levels - animal studies showed reduced fecal and serum endotoxins through competitive exclusion of Gram-negative bacteria (preliminary evidence)
• Supports infant microbiota development - superior colonization in breast-fed infants through specialized metabolism of human milk oligosaccharides (limited human trials)
• Produces beneficial short-chain fatty acids - generates lactic, butyric, and acetic acids through HMO fermentation (mechanism-based evidence)

How It Works

B. infantis ATCC 15697 encodes a unique HMO gene cluster including lacto-N-biose phosphorylase and sialidases that cleave fucosylated and sialylated oligosaccharides from breast milk, generating acetate and lactate that acidify the colonic environment to pH 5.0–5.5, inhibiting pathogen growth. The strain upregulates tight-junction proteins including occludin and claudin-1 in enterocytes, reinforcing epithelial barrier integrity and reducing translocation of lipopolysaccharide (LPS). Additionally, colonization modulates dendritic cell signaling via Toll-like receptor 2 (TLR2) and TLR4 pathways, promoting tolerogenic regulatory T-cell (Treg) responses and reducing pro-inflammatory cytokines such as IL-6 and TNF-α.

Scientific Research

Clinical evidence for ATCC 15697 is limited, with two small trials in premature infants showing superior colonization compared to B. animalis strains, particularly when combined with human milk. The primary evidence comes from a 38-day rat study (PMID: 24967382) demonstrating significant microbiota modulation, though no large-scale human RCTs or meta-analyses were identified.

Clinical Summary

A randomized controlled trial in premature infants (n=28) by Underwood et al. demonstrated that supplementation with B. infantis ATCC 15697 plus lactoferrin produced significantly higher fecal bifidobacteria counts and lower fecal pH compared to Lactobacillus reuteri or placebo, with reductions in fecal Proteobacteria exceeding 50%. A study by Frese et al. (2017) in healthy term infants showed that a single course of B. infantis EVC001 (derived from ATCC 15697) durably colonized the infant gut for at least 30 days post-supplementation, reducing urease-producing and toxin-producing bacteria. Evidence remains preliminary, largely from small infant cohorts; adult and large-scale pediatric RCT data are limited, and long-term clinical outcomes such as reduced infection rates or allergy prevention have not been confirmed in phase III trials.

Nutritional Profile

Bifidobacterium infantis ATCC 15697 is a probiotic microorganism, not a conventional food ingredient, so macronutrient and micronutrient content is not applicable in traditional dietary terms. However, its bioactive composition is well-characterized: The organism produces short-chain fatty acids (SCFAs) including acetate (primary metabolic output, approximately 40-60% of fermentation end products) and lactate as primary fermentation byproducts when consuming human milk oligosaccharides (HMOs). It encodes a uniquely complete HMO utilization gene cluster, enabling consumption of lacto-N-tetraose, lacto-N-neotetraose, and fucosyllactose. The strain produces folate (vitamin B9) endogenously during metabolism, contributing to local gut folate availability, though quantified concentrations in situ are strain-condition dependent. Cell wall components include peptidoglycans and lipoteichoic acids, which serve as microbe-associated molecular patterns (MAMPs) interacting with host toll-like receptors (TLR-2, TLR-4). The organism produces indole-3-lactic acid (ILA) and other tryptophan metabolites that interact with aryl hydrocarbon receptors (AhR), supporting intestinal barrier integrity. No dietary fiber, exogenous protein, or fat content is contributed. Typical probiotic dosing ranges from 1×10^8 to 1×10^10 CFU per serving; bioavailability of metabolic outputs is localized primarily to the colon. Protein content of the bacterial cells themselves is negligible at physiological dosing levels.

Preparation & Dosage

Clinically studied dosages for ATCC 15697 are not well-established in human trials. Infant studies used unspecified daily oral doses administered via feeding over 2 weeks, while animal studies employed microencapsulated forms given daily for 38 days without specific CFU quantification. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Human milk oligosaccharides, Lactobacillus species, Prebiotic fibers, Galacto-oligosaccharides, Other Bifidobacterium strains

Safety & Interactions

B. infantis ATCC 15697 is generally recognized as safe (GRAS) for use in healthy infants and adults, with no serious adverse events reported in published clinical trials at doses ranging from 1×10⁸ to 1.8×10¹⁰ CFU/day. Transient mild gastrointestinal symptoms including bloating and increased stool frequency have been noted in a minority of subjects. Immunocompromised individuals, including those on corticosteroids, chemotherapy, or with HIV, should use all live probiotic strains with caution due to rare documented cases of bacteremia with Bifidobacterium species. No clinically significant drug interactions have been established, though concurrent antibiotic use will substantially reduce viable cell counts and efficacy; probiotic administration should be separated from antibiotics by at least two hours.